BioPharmSignal logoBioPharmSignal

Biotech News

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Spero Therapeutics (SPRO)Spero TherapeuticsFDA / regulatory

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the US

Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment [1]

More than...

Related news

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-11-04 22:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-11-02 22:05 EST

Spero Therapeutics to Present at Investor Conferences in November

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Stock data

Close
1.02 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States